HOOKIPA Pharma Inc (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.

HOOKIPA Pharma Inc（NASDAQ:HOOK，HOOKIPA）是一家基于其专有的沙粒病毒平台开发新型免疫治疗剂的公司，今天宣布，第一人已在HB-500的1b期临床试验中服用，HB-500是一种用于治疗艾滋病毒的研究性治疗疫苗。因此，HOOKIPA根据其与Gilead的合作和许可协议实现了500万美元的非稀释里程碑付款。

The Phase 1b clinical trial (NCT06430905) will evaluate the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive antiretroviral treatment. The Phase 1b design comprises two dose escalation cohorts that will be randomized to receive HB-500 or placebo.

1b期临床试验（NCT06430905）将评估HIV抑制性抗逆转录病毒治疗参与者对重复剂量HB-500的安全性和耐受性，反应原性和免疫原性。1b期设计包括两个剂量递增队列，将随机接受HB-500或安慰剂。

The first participant was dosed on July 1, 2024, and enrollment is ongoing. “HIV impacts the daily lives of millions globally, with no known curative treatment. While current treatments effectively block viral replication and can prevent progression to AIDS, they have not been shown to clear the virus from people living with HIV, requiring lifelong treatment,” said Joern Aldag, Chief Executive Officer of HOOKIPA.

第一名参与者于2024年7月1日服用，目前正在进行登记。HOOKIPA首席执行官乔恩·奥尔达格（JoernAldag）表示：“艾滋病毒影响着全球数百万人的日常生活，目前还没有已知的治疗方法。虽然目前的治疗方法有效地阻止了病毒的复制，并可以预防艾滋病的进展，但尚未证明它们可以清除艾滋病毒感染者的病毒，需要终身治疗。”。

“We have previously published impressive findings in our preclinical studies of HB-500, and we are ha.

“我们之前在HB-500的临床前研究中发表了令人印象深刻的发现，我们是ha。